BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23625598)

  • 1. Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer.
    Łuczyńska E; Gasińska A; Wilk W
    Pol J Pathol; 2013 Apr; 64(1):33-8. PubMed ID: 23625598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Ki-67 (MIB-1) and GLUT-1 proteins in non-advanced prostatic cancer.
    Luczynska E; Gasinska A; Wilk W
    Pol J Pathol; 2012 Dec; 63(4):272-7. PubMed ID: 23359198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.
    Miyata Y; Mitsunari K; Asai A; Takehara K; Mochizuki Y; Sakai H
    Prostate; 2015 Jan; 75(1):84-91. PubMed ID: 25307287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The angiogenic switch for vascular endothelial growth factor-A and cyclooxygenase-2 in prostate carcinoma: correlation with microvessel density, androgen receptor content and Gleason grade.
    Gyftopoulos K; Vourda K; Sakellaropoulos G; Perimenis P; Athanasopoulos A; Papadaki E
    Urol Int; 2011; 87(4):464-9. PubMed ID: 21912077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive values of vascular endothelial growth factor and microvessel-density levels in initial biopsy for prostate cancer.
    Kervancioglu E; Kosan M; Erinanc H; Gonulalan U; Oguzulgen AI; Coskun EZ; Ozkardes H
    Kaohsiung J Med Sci; 2016 Feb; 32(2):74-9. PubMed ID: 26944325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
    Mazzucchelli R; Montironi R; Santinelli A; Lucarini G; Pugnaloni A; Biagini G
    Prostate; 2000 Sep; 45(1):72-9. PubMed ID: 10960845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy.
    Gasinska A; Jaszczynski J; Rychlik U; Łuczynska E; Pogodzinski M; Palaczynski M
    Pathol Oncol Res; 2020 Apr; 26(2):1049-1056. PubMed ID: 30989489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of vasohibin-1 expression in patients with prostate cancer.
    Kosaka T; Miyazaki Y; Miyajima A; Mikami S; Hayashi Y; Tanaka N; Nagata H; Kikuchi E; Nakagawa K; Okada Y; Sato Y; Oya M
    Br J Cancer; 2013 May; 108(10):2123-9. PubMed ID: 23591203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of perfusion CT parameters, microvessl density and VEGF expression in differentiation of benign and malignant prostate tumours.
    Luczynska E; Gasinska A; Blecharz P; Stelmach A; Jereczek-Fossa BA; Reinfuss M
    Pol J Pathol; 2014 Oct; 65(3):229-36. PubMed ID: 25372421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the expression of telomerase and prostate-specific membrane antigen in non-advanced prostatic cancer.
    Gasinska A; Luczynska E; Wilk W; Cichocka A
    Folia Histochem Cytobiol; 2013; 51(1):66-72. PubMed ID: 23690220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.
    Ekici S; Cerwinka WH; Duncan R; Gomez P; Civantos F; Soloway MS; Lokeshwar VB
    Int J Cancer; 2004 Oct; 112(1):121-9. PubMed ID: 15305383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
    Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
    Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma.
    Strohmeyer D; Strauss F; Rössing C; Roberts C; Kaufmann O; Bartsch G; Effert P
    Anticancer Res; 2004; 24(3a):1797-804. PubMed ID: 15274358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues.
    Pallares J; Rojo F; Iriarte J; Morote J; Armadans LI; de Torres I
    Histol Histopathol; 2006 Aug; 21(8):857-65. PubMed ID: 16691538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent prognostic importance of microvessel density in clinically localized prostate cancer.
    Halvorsen OJ; Haukaas S; Høisaeter PA; Akslen LA
    Anticancer Res; 2000; 20(5C):3791-9. PubMed ID: 11268456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of < 4.0 ng/mL.
    Sokoloff MH; Yang XJ; Fumo M; Mhoon D; Brendler CB
    BJU Int; 2004 Mar; 93(4):499-502. PubMed ID: 15008717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.
    Feneley MR; Gillatt DA; Hehir M; Kirby RS
    Br J Urol; 1996 Dec; 78(6):911-8; discussion 919-20. PubMed ID: 9014719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.